Arthur Tzianabos - 10 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Signature
/s/ Jonathan Allan, Attorney-in-Fact
Issuer symbol
STOK
Transactions as of
10 Mar 2026
Net transactions value
-$174,214
Form type
4
Filing time
12 Mar 2026, 16:57:26 UTC
Previous filing
27 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
TZIANABOS ARTHUR Interim Executive Chair, Director C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 12 Mar 2026 0001586226

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Options Exercise +3,955 +12% $8.33* 35,694 10 Mar 2026 Direct
transaction STOK Common Stock Sale $174,214 -4,355 -12% $40.00 31,339 10 Mar 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Stock Option (Right to Buy) Options Exercise -3,955 -3.2% $0.000000* 118,696 10 Mar 2026 Common Stock 3,955 $8.33 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.095 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Effective October 6, 2025, this option became fully vested and exercisable.